SPOTLIGHT -
Amir Goldkorn, MD Talks Next Steps for SWOG 1216 Trial
The University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.
Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPC
Baseline CTC counts were shown to be strong indicators for subsequent therapy response and 2-year progression-free survival.
